Tests mebendazole added to mesalamine for ulcerative colitis
Tests mebendazole with mesalamine in adults with ulcerative colitis.
Key facts
- Who runs it
- Tanta University
- Where
- Tanta, EgyptSee the site
- Trial code
- Registry title
- Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
- Status
- Recruiting
- People taking part
- 46 people, planned
- Started
- 20 Apr 2024
- Planned end
- May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mebendazole
- Record updated
- 6 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild or moderate ulcerative colitis who are already treated with mesalamine. It tests mebendazole added to this treatment.
- Age
- 18 to 75 years
- Sex
- Women and men can join.
- Disease stage
- Mild or moderate ulcerative colitis, confirmed by endoscopy.
- Earlier treatment
- Must be treated with 5-aminosalicylic acid (mesalamine). Cannot be on rectal or systemic steroids, immunosuppressants or biological therapies.
Main reasons for not taking part
- Severe ulcerative colitis
- Diabetes
- Significant liver or kidney problems
- Colorectal cancer or earlier removal of all or part of the colon
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
Who cannot take part
- Patients taking rectal or systemic steroids
- Patients on immunosuppressants or biological therapies
- Addiction to alcohol and / or drugs
- Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions
- Patients with Colorectal cancer patients
- Known allergy to the studied medications
- History of complete or partial colectomy
- Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction)
- Patients with other inflammatory diseases and active infection
- Patients with stressful condition (COPD, morbid obesity)
- Patients with liver disease
- Patients with any type of seizures (case report for mebendazole induced convulsion)
- Patients with renal disease (case report for mebendazole induced nephrotoxicity)
- Patients with coagulation disorders
- Patients on metronidazole (to avoid Stevens-Johnson syndrome)
- Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
- - Patients with severe UC
- Significant liver and kidney function abnormalities
- Diabetic patients
- Patients with thrombocytopenia and neutropenia
- Patients using antioxidants
- Pregnant and lactating females
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in Egypt
- Tanta UnuversityTanta, EgyptContact: Eman Elberri, PhDTaking people
About the trial
What the trial wants to find out
To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine
The 2 groups in the trial
- Control GroupNo study treatment, for comparison
control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
- Treatment GroupExisting treatment, for comparison
Treatment group( mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
Treatment: Mebendazole
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Study to Evaluate the Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
- Plain-language title
- Tests mebendazole added to mesalamine for ulcerative colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06335160, who can take part
- Record updated
- 6 February 2026